{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:07:59Z","timestamp":1790734079130,"version":"4.1.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the Chinese Pharmaceutical Association Hospital Pharmacy department","award":["No. CPA-Z05-ZC-2023002"],"award-info":[{"award-number":["No. CPA-Z05-ZC-2023002"]}]},{"name":"the Open Project of Key Laboratory of Hematology, Guangxi Medical University","award":["GXHKL202305"],"award-info":[{"award-number":["GXHKL202305"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Patients with chronic phase CML receiving frontline imatinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A retrospective study was used to evaluate the blood concentration, effectiveness, and safety of generic in 170 CML patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Imatinib plasma concentrations were detected by high-performance liquid chromatography-tandem mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 170 patients, 73 (42.9%) patients treated with branded imatinib as first-line therapy, while 22 (12.9%) switched to generic imatinib during treatment due to economic considerations. No significant differences in trough concentrations between branded and generic imatinib (1549.9\u2009\u00b1\u2009648.8\u2009ng\/mL vs 1479.0\u2009\u00b1\u2009507.0\u2009ng\/mL; p\u2009=\u20090.95). During the 2-year follow-up, there were no significant differences in molecular response rates (major molecular response (MMR): 33.3% vs 37.0%; deep molecular response: 56.9% vs 42.9%, p\u2009=\u20090.17) between the branded and generic imatinib. Both groups showed similar rates of switching to second-generation tyrosine kinase inhibitor (11.8% vs 15.1%, p\u2009=\u20090.56). Furthermore, there were no significant differences in event-free survival or failure-free survival between branded and generic imatinib. Twenty-two (12.9%) switched to generic imatinib during treatment, 68.2% maintained their level of response, 27.3% improved, and only one patient (4.5%) lost MMR. There were no significant differences in the incidence of various adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Generic imatinib are equally effective and safe compared to branded molecules, both for newly diagnosed patients and those who switch from branded.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207241270806","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T03:38:15Z","timestamp":1723693095000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparable efficacy and safety of generic and branded imatinib for patients with chronic myeloid leukemia in China"],"prefix":"10.1177","volume":"15","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Key Laboratory of Hematology, Guangxi Medical University, Education Department of the Guangxi Zhuang Autonomous Region, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-9002","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"},{"name":"Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"bibr1-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.50"},{"key":"bibr2-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1151356"},{"key":"bibr3-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"bibr4-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw003"},{"key":"bibr5-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214522143"},{"key":"bibr6-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113718"},{"key":"bibr7-20406207241270806","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.904508"},{"key":"bibr8-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12937"},{"key":"bibr9-20406207241270806","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222000"},{"key":"bibr10-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2594-8"},{"key":"bibr11-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-005686"},{"key":"bibr12-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"bibr13-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"bibr14-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34478"},{"key":"bibr15-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.033"},{"key":"bibr16-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.88"},{"key":"bibr17-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1485907"},{"key":"bibr18-20406207241270806","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.885515"},{"key":"bibr19-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.05.006"},{"key":"bibr20-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.01.009"},{"key":"bibr21-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04096-1"},{"key":"bibr22-20406207241270806","doi-asserted-by":"publisher","DOI":"10.5045\/br.2020.2020130"},{"key":"bibr23-20406207241270806","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.09.018"},{"key":"bibr24-20406207241270806","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.893302"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207241270806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207241270806","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207241270806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:10Z","timestamp":1777591030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207241270806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"alternative-id":["10.1177\/20406207241270806"],"URL":"https:\/\/doi.org\/10.1177\/20406207241270806","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"20406207241270806"}}